Generic medicines are now a structural part of pharmaceutical markets. In the US, they account for 90%+ of prescriptions but less than 13% of spending, while generics exceed three-quarters of pharmaceutical volume in several OECD markets.
However, adoption varies with patent expiry, prescribing practices, reimbursement, competition and supply economics. For manufacturers and investors, the key question is where substitution can expand while remaining commercially
How Nexdigm Evaluates the Economics Behind Generic Substitution
Nexdigm examines generic adoption through the interaction of price pressure, competitive intensity and substitution mechanisms. Lower prices can encourage switching, but the commercial opportunity depends on how much volume can be captured and whether competition allows manufacturers to maintain viable economics.
The assessment considers generic and branded price differentials, number of competitors, procurement mechanisms, reimbursement policies and prescribing practices. It also examines how these factors vary across therapy areas and markets.
This helps pharmaceutical companies distinguish between a market where generic adoption is expanding and commercially attractive and one where high penetration has already produced intense competition and limited pricing
Patent Expiry Creates the Opening
Generic demand often accelerates when branded products lose market exclusivity.
The commercial sequence is familiar: an originator reaches the end of its protected period, generic manufacturers enter, competition increases and prices begin to adjust. But the scale and speed of substitution vary considerably.
OECD data shows this clearly. In 2023, generics represented more than three-quarters of pharmaceutical volume in several OECD markets, while their share remained below one-quarter in others. The OECD attributes these differences partly to market structure and prescribing practices, as well as government policies.
For manufacturers, patent expiry should therefore be treated as an entry signal rather than a guaranteed opportunity.
A product coming off patent may attract numerous competitors, creating volume but severe price erosion. Another may face limited competition because manufacturing is complex, demand is small or regulatory requirements are more demanding.
Substitution Depends on Who Controls the Decision
Generic adoption is shaped by the mechanics of prescribing and dispensing.
In some healthcare systems, pharmacists can substitute a generic for the originator. In others, physicians retain greater control over product selection. Public procurement and hospital tenders can shift purchasing power toward the lowest-cost compliant supplier.
OECD data shows how different these systems can be. In Austria, pharmacist substitution is not permitted, while Luxembourg permits it only for selected medicines. These structural differences help explain why generic penetration varies substantially between otherwise comparable markets.
For a pharmaceutical company, this makes stakeholder mapping commercially important.
The assessment needs to establish who prescribes, who dispenses, who pays and who determines reimbursement. Those four decisions can determine the speed at which a generic gains share.
High Penetration Can Mean Both Opportunity and Saturation
Generic demand often rises after branded products lose exclusivity, but the commercial outcome depends on the competitive response.
- Patent expiry opens the market: Generic manufacturers can enter once exclusivity ends.
- Competition determines value: More entrants can increase volume but accelerate price erosion.
- Adoption varies by market: In 2023, generics exceeded three-quarters of pharmaceutical volume in several OECD markets but remained below one-quarter in others.
- Entry potential differs by product: Complex manufacturing, limited demand or regulatory barriers can restrict competition.
For manufacturers, patent expiry is an entry signal, not a guarantee of commercial attractiveness.
The Lowest Price Is Not Always the Best Market
- Lower prices drive adoption: Greater affordability can accelerate generic uptake.
- Price erosion can weaken margins: Heavy competition can reduce manufacturer incentives to remain in a market.
- Supply can become vulnerable: Weak economics may contribute to manufacturers exiting low-margin products.
- Market structure matters: Manufacturer concentration, production costs and supply reliability should be assessed alongside demand.
A strong generic market therefore needs both substitution potential and sustainable supplier economics.
How Nexdigm Assesses Generic Drug Demand
- Market & Therapy Sizing
Nexdigm measures branded and generic volumes, treatment penetration, therapy-area demand and market growth to determine where meaningful substitution potential exists. - Substitution Environment
The assessment examines patent expiry, prescribing practices, pharmacist substitution, procurement mechanisms and reimbursement policies to understand what can accelerate generic uptake. - Competitive Economics
Nexdigm maps manufacturers, market shares, pricing and expected entrants to assess competition and potential price erosion. - Access & Supply Sustainability
Regulatory requirements, distribution networks, manufacturing capacity and availability are assessed to determine whether demand can be converted into reliable supply. - Market Prioritization
The findings are combined to rank therapy areas and geographies according to demand potential, substitution likelihood, competitive intensity and sustainable economics.
This turns generic-market research into an investment decision: which markets are likely to expand, why will substitution occur, and can a new entrant capture value without undermining the economics of the category?
Nexdigm’s Generic Drug Market Assessment
Nexdigm’s analysis of Saudi Arabia examined 11 therapeutic classes, assessing generic adoption, spending and substitution potential. The study evaluated how changing generic penetration could affect pharmaceutical spending and identified opportunities for greater substitution across the selected therapy areas.
Generic demand is ultimately shaped by cost pressure, policy, substitution behaviour, competition and supply economics. Nexdigm’s generic drug demand assessment connects these variables to identify where generic adoption can create a commercially sustainable opportunity rather than simply a high-volume market.
To take the next step, simply visit our Request a Consultation page and share your requirements with us.
Harsh Mittal
+91-8422857704
[email protected]